ישראל - עברית - Ministry of Health

rafa laboratories ltd - fluconazole - קפסולות - fluconazole 50 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - fluconazole - קפסולות - fluconazole 200 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 200 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei),serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ישראל - עברית - Ministry of Health

j-c health care ltd - guselkumab - תמיסה להזרקה - guselkumab 100 mg / 1 ml - guselkumab

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - אבקה להכנת תרחיף - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - cryptoccosis including cryptoccocal meningitis, systemic candidiasis including candidemia, mucosal candidiasis, vaginal candidiasis, dermatomycosis all as specified in leaflet.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - קפסולות - fluconazole 200 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.